Effects of Exenatide on Measures of β-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: We previously showed that exenatide (EXE) enhanced insulin secretion after 1 year of treatment, relative to insulin glargine (GLAR), with a similar glucose-lowering action. These effects were not sustained after a 4-week off-drug period. This article reports the results after additional 2 years of exposure. RESEARCH DESIGN AND METHODS: Sixty-nine metformin-treated patients with type 2 diabetes were randomized to EXE or GLAR. Forty-six patients entered the 2-year extension study in which they continued their allocated therapy. Thirty-six completed (EXE: n = 16; GLAR: n = 20) the 3-year exposure period. Insulin sensitivity (M value) and β-cell function were measured by euglycemic hyperinsulinemic clamp followed by hyperglycemic clamp with arginine stimulation at pretreatment (week 52) and 4 weeks after discontinuation of study medication (week 56 and week 172). First-phase glucose stimulated C-peptide secretion was adjusted for M value and calculated as the disposition index (DI). RESULTS: At 3 years, EXE and GLAR resulted in similar levels of glycemic control: 6.6 ± 0.2% and 6.9 ± 0.2%, respectively (P = 0.186). EXE compared with GLAR significantly reduced body weight (−7.9 ± 1.8 kg; P < 0.001). After the 4-week off-drug period, EXE increased the M value by 39% (P = 0.006) while GLAR had no effect (P = 0.647). Following the 4-week off-drug period, the DI, compared with pretreatment, increased with EXE, but decreased with GLAR (1.43 ± 0.78 and −0.99 ± 0.65, respectively; P = 0.028). CONCLUSIONS: EXE and GLAR sustained HbA1c over the 3-year treatment period, while EXE reduced body weight and GLAR increased body weight. Following the 3-year treatment with EXE, the DI was sustained after a 4-week off-drug period. These findings suggest a beneficial effect on β-cell health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“none of these agents have produced a meaningful, persistent change following therapy withdrawal ( 71 , 73 ).”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [73]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The long-term effects of GLP-1RA go beyond the improvement in glucose metabolism and weight loss [34,35,36,37,38,39] and it is now established their beneficial effects of hepatic metabolism and histology.”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [35]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Further analyses from TODAY show that in youth with type 2 diabetes dyslipidaemia162 and hypertension163 are common and worsen over time.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [162]
Experimental — accuracy not yet measuredIn the citing paper
“In one study of exenatide,25 patients underwent two treatment phases—52 weeks followed by 104 weeks—with a 12-week off-treatment period after each phase.”
From Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression (2026) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 3×
“EXE predominantly lowers postprandial glucose by a glucose-dependent stimulation of insulin secretion, inhibition of an inappropriate glucagon secretion, and by slowing down gastric emptying (6).”
BackgroundResultInfluentialNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“Although human data are not available, exposure to GLP-1 and GLP-1RA in the preclinical setting results in b-cell proliferation, islet neogenesis, and inhibition of b-cell apoptosis in (human) cell lines, primary rodent islets, and in vivo in different rodent species (13).”
BackgroundKahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., & Palmer, J. P. (1993) · Diabetes · doi:10.2337/diab.42.11.1663 · Cited by 1,405 · cited 2×
“The disposition index (DI), a measure of b-cell function and adjusted for insulin sensitivity, was calculated bymultiplying the firstphase incremental C-peptide secretion with the M value (AIRgluc*M) (12).”
BackgroundMethodZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 1×
“(21) was the first to report a beneficial effect of continuous GLP-1 infusion on clamp-measured b-cell function as well as insulin sensitivity in the presence of concomitant weight loss of 1.”
BackgroundCauter, E. V., Mestrez, F., Sturis, J., & Polonsky, K. S. (1992) · Diabetes · doi:10.2337/diab.41.3.368 · Cited by 890
DeFronzo, R. A. (2010) · Diabetologia · doi:10.1007/s00125-010-1684-1 · Cited by 879
Cited by
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
“No meaningful differenceswere seen in HbA1c ormultiple measures of b cell function across different treatment groups (Bunck et al., 2011).”
BackgroundInfluentialGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment
Halban, P. A., Polonsky, K. S., Bowden, D. W., Hawkins, M. A., Ling, C., Mather, K. J., Powers, A. C., Rhodes, C. J., Sussel, L., & Weir, G. C. (2014) · Diabetes Care · doi:10.2337/dc14-0396 · Cited by 460
Butler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C. (2013) · Diabetes · doi:10.2337/db12-1686 · Cited by 457
Tan, S. Y., Mei Wong, J. L., Sim, Y. J., Wong, S. S., Mohamed Elhassan, S. A., Tan, S. H., Ling Lim, G. P., Rong Tay, N. W., Annan, N. C., Bhattamisra, S. K., et al. (2019) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2018.10.008 · Cited by 445
Effects of GLP-1 on appetite and weight
Shah, M., & Vella, A. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9289-5 · Cited by 352
Russell-Jones, D., Cuddihy, R. M., Hanefeld, M., Kumar, A., González, J. G., Chan, M., Wolka, A. M., Boardman, M. K., & on behalf of the DURATION-4 Study Group (2012) · Diabetes Care · doi:10.2337/dc11-1107 · Cited by 339
Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells
Lee, Y.-S., & Jun, H.-S. (2014) · Metabolism · doi:10.1016/j.metabol.2013.09.010 · Cited by 315
“[36] Bunck MC, Corner A, Eliasson B, et al.”
BackgroundResultPathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., Eldor, R., & Abdul-Ghani, M. (2013) · Diabetes Care · doi:10.2337/dcs13-2011 · Cited by 314
Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
van Bloemendaal, L., ten Kulve, J. S., la Fleur, S. E., Ijzerman, R. G., & Diamant, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0414 · Cited by 312
“It is worthy of note, however, that when exenatide BID was discontinued after 3 years of exposure, patients started to regain weight during the 12-week washout period (Bunck et al. 2011).”
Self-citationRobinson, L. E., Holt, T. A., Rees, K., Randeva, H. S., & O'Hare, J. P. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-001986 · Cited by 296
Assessment of Pancreatic β-Cell Function: Review of Methods and Clinical Applications
Cersosimo, E., Solis-Herrera, C., Trautmann, M., Malloy, J., & Triplitt, C. (2014) · Current Diabetes Reviews · doi:10.2174/1573399810666140214093600 · Cited by 281
“Equations compiled from references [4, 6, 10, 12, 21-26, 29-31, 34, 35, 133, 134].”
BackgroundIncretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls
Drucker, D. J. (2013) · Diabetes · doi:10.2337/db13-0822 · Cited by 272
“There is little evidence that in subjects with T2D prolonged therapy with GLP-1R agonists modifies the progressive decline in b-cell function, an indirect surrogate of b-cell mass, independent of changes in weight loss (34).”
Backgroundβ-cell dysfunction: Its critical role in prevention and management of type 2 diabetes
Saisho, Y. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i1.109 · Cited by 263
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 258
Suzuki, K., Jayasena, C. N., & Bloom, S. R. (2012) · Experimental Diabetes Research · doi:10.1155/2012/824305 · Cited by 227
“A three-year duration of treatment with exenatide has been reported to improve beta cell function; however, when adjusting for weight loss associated with exenatide therapy, this effect remains speculative [79].”
Backgroundβ-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment
Halban, P. A., Polonsky, K. S., Bowden, D. W., Hawkins, M. A., Ling, C., Mather, K. J., Powers, A. C., Rhodes, C. J., Sussel, L., & Weir, G. C. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1425 · Cited by 222
“term treatments with DPP-4 inhibitors (70) and GLP-1 receptor agonists (71, 72) However, while augmented insulin production as assessed with glucose- and arginine-stimulation continues during active treatment and is of clinical value, none of these agents has produced a meaningful, persistent change following therapy…”
BackgroundThe dynamic plasticity of insulin production in β-cells
Boland, B. B., Rhodes, C. J., & Grimsby, J. S. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.04.010 · Cited by 194
Combination therapy with GLP ‐1 receptor agonist and SGLT2 inhibitor
DeFronzo, R. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12982 · Cited by 192
“This effect is mediated via the GLP-1 receptor, is observed within 8 hours(29) and persists for at least 3 years.(28) The SGLT2i also augment beta cell function,(31) but their effect is mediated indirectly via reversal of glucotoxicity.”
BackgroundAbdul‐Ghani, M. A., Puckett, C., Triplitt, C., Maggs, D., Adams, J., Cersosimo, E., & DeFronzo, R. A. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12417 · Cited by 208
“Previous studies have consistently reported that both pioglitazone [13–15] and exenatide [21,22,28] improve β-cell function in T2DM, while pioglitazone is a potent insulin sensitizer [12].”
BackgroundResultType 2 Diabetes: The Pathologic Basis of Reversible β-Cell Dysfunction
White, M. G., Shaw, J. A. M., & Taylor, R. (2016) · Diabetes Care · doi:10.2337/dc16-0619 · Cited by 174
“Use of exenatide over 3 years caused considerable weight loss and brought about some return of b-cell function (70).”
BackgroundGallwitz, B., Guzman, J., Dotta, F., Guerci, B., Simó, R., Basson, B. R., Festa, A., Kiljański, J., Sapin, H., Trautmann, M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60479-6 · Cited by 159
Seufert, J., & Gallwitz, B. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12251 · Cited by 156
“In people with type 2 diabetes, GLP-1RAs have been shown to provide numerous pancreatic effects, leading to clinically significant improvements in HbA1c, fasting plasma glucose, postprandial plasma glucose and markers of pancreatic betacell function [10–13].”
BackgroundCardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
Abdul-Ghani, M., DeFronzo, R. A., Del Prato, S., Chilton, R., Singh, R., & Ryder, R. E. J. (2017) · Diabetes Care · doi:10.2337/dc16-2736 · Cited by 145
“RAs exert a powerful effect to increase b-cell function (52,61–63) and indirectly improve insulin sensitivity by promoting weight loss (62).”
BackgroundBalena, R., Hensley, I. E., Miller, S., & Barnett, A. H. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12025 · Cited by 142
“suggested that long-term exenatide BID treatment (3 years) produced a small, durable improvement in β-cell function which persisted 4 weeks after discontinuation of exenatide BID [27].”
BackgroundPersonalized Management of Hyperglycemia in Type 2 Diabetes
Raz, I., Riddle, M. C., Rosenstock, J., Buse, J. B., Inzucchi, S. E., Home, P. D., Del Prato, S., Ferrannini, E., Chan, J. C. N., Leiter, L. A., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0512 · Cited by 143
Abd El Aziz, M. S., Kahle, M., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12804 · Cited by 155
β-Cell function in type 2 diabetes
Ferrannini, E., & Mari, A. (2014) · Metabolism · doi:10.1016/j.metabol.2014.05.012 · Cited by 164
“This is the case even with incretin mimetics (GLP-1 receptor agonists [83] and DPP-4 inhibitors [84]) notwithstanding that these molecules induce clear β-cell proliferation in rodent models [85].”
BackgroundRetnakaran, R., Kramer, C. K., Choi, H., Swaminathan, B., & Zinman, B. (2014) · Diabetes Care · doi:10.2337/dc14-0893 · Cited by 136
“The authors subsequently reported that when 52% of the original study population (n = 36) continued therapy for 3 years, there was a small, but statistically significant effect on b-cell function 4 weeks after stopping exenatide (34).”
GLP-1 receptor signalling promotes β-cell glucose metabolism via mTOR-dependent HIF-1α activation
Carlessi, R., Chen, Y., Rowlands, J., Cruzat, V. F., Keane, K. N., Egan, L., Mamotte, C., Stokes, R., Gunton, J. E., Bittencourt, P. I. H. D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-02838-2 · Cited by 122
Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes
Cahn, A., & Cefalu, W. T. (2016) · Diabetes Care · doi:10.2337/dcs15-3007 · Cited by 118
“Administration of exenatide for 172 weeks resulted in superior b-cell function compared with glargine, an effect that was partially maintained even after drug cessation (26).”
BackgroundNew forms of insulin and insulin therapies for the treatment of type 2 diabetes
Cahn, A., Miccoli, R., Dardano, A., & Prato, S. D. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00097-2 · Cited by 114
Paneni, F., & Lüscher, T. F. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.008 · Cited by 127
“Moreover, the reduction of HbA1c levels with these drugs is long-lasting, and this is mostly due to a durable effect on the pancreatic b-cell to enhance insulin secretion.(62) The receptor for GLP-1 is abundantly expressed in the vascular endothelium, smooth muscle cells, and cardiomyocytes, suggesting that these drug…”
BackgroundEmpagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus
Al Jobori, H., Daniele, G., Adams, J., Cersosimo, E., Solis-Herrera, C., Triplitt, C., DeFronzo, R. A., & Abdul-Ghani, M. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01838 · Cited by 103
“, sulfonylureas, glinides, incretins, thiazolidinediones) augment insulin secretion, only the GLP-1 receptor agonists (20) and thiazolidinediones (21, 22) improve b-cell function on a long-term basis.”
BackgroundDesign of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists
Evers, A., Haack, T., Lorenz, M., Bossart, M., Elvert, R., Henkel, B., Stengelin, S., Kurz, M., Glien, M., Dudda, A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00174 · Cited by 101
GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes
Wilbon, S. S., & Kolonin, M. G. (2023) · Cells · doi:10.3390/cells13010065 · Cited by 101
“Although this post-withdrawal effect did not translate to improved glycemic control, it does show that some beneficial alterations in β cell function are preserved with more long-term treatment [19].”
BackgroundThe RISE Consortium (2014) · Diabetes Care · doi:10.2337/dc13-1879 · Cited by 100
“baseline but much reduced compared with the on-treatment measures (35).”
Glucagon-like peptides 1 and 2 in health and disease: A review
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013) · Peptides · doi:10.1016/j.peptides.2013.01.014 · Cited by 100
Newer GLP-1 receptor agonists and obesity-diabetes
Brown, E. E., Cuthbertson, D. J., & Wilding, J. P. H. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.009 · Cited by 110
Coming full circle in diabetes mellitus: from complications to initiation
Harcourt, B. E., Penfold, S. A., & Forbes, J. M. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.236 · Cited by 97
Paneni, F., & Lüscher, T. F. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.015 · Cited by 83
Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies
Szczesnowicz, A., Szeliga, A., Niwczyk, O., Bala, G., & Meczekalski, B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185915 · Cited by 83
“[32].”
Kanat, M., DeFronzo, R. A., & Abdul-Ghani, M. A. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i12.1207 · Cited by 82
Evolution of Exenatide as a Diabetes Therapeutic
Bhavsar, S., Mudaliar, S., & Cherrington, A. (2013) · Current Diabetes Reviews · doi:10.2174/157339913805076472 · Cited by 81
Combination immunotherapies for type 1 diabetes mellitus
Pozzilli, P., Maddaloni, E., & Buzzetti, R. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.8 · Cited by 83
Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin
Vanderheiden, A., Harrison, L. B., Warshauer, J. T., Adams-Huet, B., Li, X., Yuan, Q., Hulsey, K., Dimitrov, I., Yokoo, T., Jaster, A. W., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3906 · Cited by 76
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Cahen, D. L., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12593 · Cited by 74
“Currently available clinical studies have shown a sustained effect on glycaemic control of up to 3 years [56]; however, after cessation of therapy, no lasting effect on insulin secretion is seen [57,58].”
BackgroundManaging insulin resistance: the forgotten pathophysiological component of type 2 diabetes
Abdul-Ghani, M. A., Maffei, P., & DeFronzo, R. A. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00127-x · Cited by 89
The RISE Consortium, Ehrmann, D. A., Temple, K. A., Rue, A., Barengolts, E., Mokhlesi, B., Van Cauter, E., Sam, S., Miller, M. A., Kahn, S. E., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0556 · Cited by 73
Diabetic ketoacidosis: A common debut of diabetes among African Americans with type 2 diabetes
Vellanki, P., & Umpierrez, G. E. (2017) · Endocrine Practice · doi:10.4158/ep161679.ra · Cited by 73
Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury
Higashijima, Y., Tanaka, T., Yamaguchi, J., Tanaka, S., & Nangaku, M. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00590.2014 · Cited by 69
“Lipopolysaccharide induces macrophage migration via prostaglandin D(2) and 482 prostaglandin E(2).”
BackgroundTzang, C.-C., Wu, P.-H., Luo, C.-A., Chen, Z.-T., Lee, Y.-T., Huang, E. S., Kang, Y.-F., Lin, W.-C., Tzang, B.-S., & Hsu, T.-C. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103680 · Cited by 73
“22 In Aronne 2024 and Rubino 2021, the alternate arm continued GLP-1RA treatment and were not included in the placebo-withdrawal analyses.”
Importance of Beta Cell Function for the Treatment of Type 2 Diabetes
Saisho, Y. (2014) · Journal of Clinical Medicine · doi:10.3390/jcm3030923 · Cited by 82
“Although an increase in beta cell mass with incretin therapy has been reported in rodent studies [110,111], this effect has not been confirmed in humans [112–114].”
BackgroundLim, S. K., Kim, K. M., & Nauck, M. A. (2018) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2018.01.011 · Cited by 76
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
Armato, J., DeFronzo, R. A., Abdul-Ghani, M. A., & Ruby, R. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30234-1 · Cited by 70
Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption
ten Kulve, J. S., Veltman, D. J., van Bloemendaal, L., Groot, P. F. C., Ruhé, H. G., Barkhof, F., Diamant, M., & Ijzerman, R. G. (2016) · Journal of Endocrinology · doi:10.1530/joe-15-0461 · Cited by 66
“with dose-escalation period based on their fasting self-monitored blood glucose levels according to a predetermined treat-to-target algorithm (Bunck et al. 2011).”
MethodSelf-citationEmerging Treatment Strategies for Diabetes Mellitus and Associated Complications: An Update
Mishra, V. K., Nayak, P., Sharma, M., Albutti, A., Alwashmi, A. S. S., Aljasir, M. A., Alsowayeh, N., & Tambuwala, M. M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101568 · Cited by 77
“GLP-1 analogs are incretin-based treatments that enhance insulin secretion via a glucose-dependent style, decline the glucagon secretion and reduce the hepatic glucose production [22].”
BackgroundAbdul-Ghani, M., & DeFronzo, R. A. (2017) · Diabetes Care · doi:10.2337/dc16-2368 · Cited by 62
“, improving b-cell glucose sensitivity; this beneficial effect on the b-cell can be observed within 8 h after a single injection of the GLP-1 RA (liraglutide) (33), is maintained at 3 months (semaglutide) (34), and persists for at least 3 years (exenatide) (35).”
BackgroundClinical pharmacology of glucagon-like peptide-1 receptor agonists
Sfairopoulos, D. G., Liatis, S., Tigas, S. K., & Liberopoulos, E. N. (2018) · HORMONES · doi:10.1007/s42000-018-0038-0 · Cited by 73
Combining GLP ‐1 receptor agonists with insulin: therapeutic rationales and clinical findings
Holst, J. J., & Vilsbøll, T. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01628.x · Cited by 63
van Raalte, D. H., & Verchere, C. B. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12935 · Cited by 69
Xu, W., Bi, Y., Sun, Z., Li, J., Guo, L., Yang, T., Wu, G., Shi, L., Feng, Z., Qiu, L., et al. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12293 · Cited by 58
Interventions to Preserve Beta-Cell Function in the Management and Prevention of Type 2 Diabetes
Page, K. A., & Reisman, T. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0363-2 · Cited by 64
Wu, T., Rayner, C. K., & Horowitz, M. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_9 · Cited by 68
Harris, K. B., & McCarty, D. J. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814558242 · Cited by 57
An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass
Chon, S., & Gautier, J. (2016) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2016.40.2.99 · Cited by 66
“[70], improvements in β-cell function, as assessed by an increase in disposition index, persisted in the exenatide group 4 weeks after drug discontinuation in a subgroup analysis of 217 patients during a 3-year follow-up period.”
BackgroundAbdul-Ghani, M., Puckett, C., Adams, J., Khattab, A., Baskoy, G., Cersosimo, E., Triplitt, C., & DeFronzo, R. A. (2021) · Diabetes Care · doi:10.2337/dc20-0978 · Cited by 55
Bariatric surgery and obesity: influence on the incretins
Laferrère, B. (2016) · International Journal of Obesity Supplements · doi:10.1038/ijosup.2016.8 · Cited by 57
Effect of LX4211 on Glucose Homeostasis and Body Composition in Preclinical Models
Powell, D. R., DaCosta, C. M., Smith, M. G., Doree, D. D., Harris, A. L., Buhring, L., Heydorn, W. E., Nouraldeen, A. M., Xiong, W., Yalamanchili, P., et al. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.214304 · Cited by 58
MARTINEZ, R. A., Jobori, H. A., Ali, A. M., Adams, J. M., Abdul-Ghani, M. A., Triplitt, C. L., DeFronzo, R. A., & Cersósimo, E. (2018) · Diabetes · doi:10.2337/db17-1278 · Cited by 57
“Glucagon-like peptide 1 (GLP-1) receptor agonists are potent insulin secretagogues and inhibit glucagon secretion (11,12).”
BackgroundBudini, B., Luo, S., Tam, M., Stead, I., Lee, A., Akrami, A., Vidal-Puig, A., & Park, A. (2026) · eClinicalMedicine · doi:10.1016/j.eclinm.2026.103796 · Cited by 52
Cersosimo, E., Johnson, E. L., Chovanes, C., & Skolnik, N. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13108 · Cited by 52
Fiorentino, T. V., Casiraghi, F., Davalli, A. M., Finzi, G., La Rosa, S., Higgins, P. B., Abrahamian, G. A., Marando, A., Sessa, F., Perego, C., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.93091 · Cited by 51
“However, after 3 years of treatment, exenatide resulted in increased insulin sensitivity along with improved β cell function that were sustained after cessation of treatment for 4 weeks (40).”
BackgroundRemillard, C., MacConell, Li, Pencek, Maggs, & Porter (2013) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s35801 · Cited by 50
“Improvement in the disposition index after a 4-week off-drug period in patients treated with ExBID for 3 years was also reported.(12) In randomized, controlled trials, ExBID treatment was associated with improvements in hemoglobin A 1c (HbA 1c ) and cardiometabolic measures such as body weight, lipid profile, and bloo…”
Basal Insulin Use With GLP-1 Receptor Agonists
Anderson, S. L., & Trujillo, J. M. (2016) · Diabetes Spectrum · doi:10.2337/diaspect.29.3.152 · Cited by 58
The regulation of function, growth and survival of GLP-1-producing L-cells
Kuhre, R. E., Holst, J. J., & Krizhanovskii, C. (2015) · Clinical Science · doi:10.1042/cs20150154 · Cited by 54
Liu, J., Hu, Y., Zhang, H., Xu, Y., & Wang, G. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.07.020 · Cited by 54
Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance
Tella, S. H., & Rendell, M. S. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018815580257 · Cited by 46
“In a very significant small study, β-cell secretion was measured by glucose clamp over a 3-year period in patients treated with exenatide compared with those treated with glargine [Bunck et al. 2011].”
ResultFirst-phase insulin secretion: can its evaluation direct therapeutic approaches?
Di Giuseppe, G., Ciccarelli, G., Soldovieri, L., Capece, U., Cefalo, C. M. A., Moffa, S., Nista, E. C., Brunetti, M., Cinti, F., Gasbarrini, A., et al. (2023) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2023.02.001 · Cited by 46
“6 mmol/l) (52 weeks) ↑ AIRARG during HC in the EXE group compared to the GLAR group ↑ First-phase C-peptide secretion during HC in the EXE group compared to the GLAR group [122]”
Ekström, N., Svensson, A., Miftaraj, M., Franzén, S., Zethelius, B., Eliasson, B., & Gudbjörnsdottir, S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12704 · Cited by 46
“Missing values, n (%) 130 (54) 1607 (37) 594 (28) 67 (31) 986 (44) 3458 (39) 1253 (50)”
Self-citationDiabetes and disordered bone metabolism (diabetic osteodystrophy): time for recognition
Epstein, S., Defeudis, G., Manfrini, S., Napoli, N., & Pozzilli, P. (2016) · Osteoporosis International · doi:10.1007/s00198-015-3454-x · Cited by 48
“PTH-independent osteogenic effect [113] In humans, a 44-week treatment of exenetide did not affect BMD and bone markers [114].”
BackgroundSemaglutide seems to be more effective the other GLP-1Ras
Holst, J. J., & Madsbad, S. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.11.10 · Cited by 45
GLP-1 as a target for therapeutic intervention
Rajeev, S. P., & Wilding, J. P. H. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.08.005 · Cited by 45
Gudipaty, L., Rosenfeld, N. K., Fuller, C. S., Gallop, R., Schutta, M. H., & Rickels, M. R. (2014) · Diabetes Care · doi:10.2337/dc14-0398 · Cited by 41
“Changes in weight over time were not significantly different across the three groups [F(12, 222) = 1.”
Functional loss of pancreatic islets in type 2 diabetes: How can we halt it?
Marrano, N., Biondi, G., Cignarelli, A., Perrini, S., Laviola, L., Giorgino, F., & Natalicchio, A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154304 · Cited by 41
Remission of type 2 diabetes: always more questions, but enough answers for action
Rothberg, A. E., Lean, M. E. J., & Laferrère, B. (2024) · Diabetologia · doi:10.1007/s00125-023-06069-1 · Cited by 56
“GLP-1 receptor agonists provide weight loss with enhancement of beta cell function and glucose con-trol, but the effect is rapidly lost on cessation of medication [36–38].”
BackgroundAbdul-Ghani, M., Migahid, O., Megahed, A., Adams, J., Triplitt, C., DeFronzo, R. A., Zirie, M., & Jayyousi, A. (2017) · Diabetes Care · doi:10.2337/dc16-1738 · Cited by 39
Zheng, S., Zhang, Y., Long, T., Lu, J., Liu, X., Yan, J., Chen, L., Gong, Y., & Wang, F. (2017) · Obesity Medicine · doi:10.1016/j.obmed.2017.06.003 · Cited by 45
Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm
Wilding, J. P. H., Rajeev, S. P., & DeFronzo, R. A. (2016) · Diabetes Care · doi:10.2337/dcs15-3005 · Cited by 43
“However, endogenous human GLP-1 has a short half-life (2–3min) due to breakdown in the circulation by protease enzymes, notably, dipeptidyl peptidase (DPP)-4, which cleaves the molecule to leave the inactive GLP-1 (9-36).”
BackgroundIncretin-based therapies in prediabetes: Current evidence and future perspectives
Papaetis, G. S. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i6.817 · Cited by 37
Wu, H., Yang, W., Guo, T., Cai, X., & Ji, L. (2025) · BMC Medicine · doi:10.1186/s12916-025-04200-0 · Cited by 36
Brunton, S. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12675 · Cited by 43
Shao, N., Yu, X., Yu, Y.-M., Li, B., Pan, J., Wu, W.-H., Zhang, H.-J., Ma, X., Hao, M., & Kuang, H. (2018) · Andrologia · doi:10.1111/and.13039 · Cited by 39
“…and it has multiple biological effects, including improvements of glycemic control, lipid metabolism and insulin resistance (IR), preservation of β cell function, reductions in blood pressure and body weight (Bunck et al., 2011; Klonoff et al., 2008; Okerson, Yan, Stonehouse, & Brodows, 2010).”
BackgroundIslet Number Rather Than Islet Size Is a Major Determinant of β- and α-Cell Mass in Humans
Kou, K., Saisho, Y., Sato, S., Yamada, T., & Itoh, H. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3731 · Cited by 35
Guo, X.-H. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1103214 · Cited by 33
Ethnic Similarities and Differences in the Relationship between Beta Cell Mass and Diabetes
Inaishi, J., & Saisho, Y. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6120113 · Cited by 38
Metadata
- Authors
- Bunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Taskinen, M.-R., Smith, U., Yki-Järvinen, H., & Diamant, M.
- Affiliations
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Helsinki University Hospital (FI)
- Lundberg Laboratory for Diabetes Research, Sahlgrenska University Hospital, Goteborg, Sweden
- Eli Lilly (United States) (US)
- Eli Lilly (Netherlands) (NL)
- Sahlgrenska University Hospital (SE)
- Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
- Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, the Netherlands
- Corresponding author
- Bunck, Mathijs C.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-08-19
- Volume
- 34
- Issue
- 9
- Pages
- 2041-2047
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3161303
- OpenAlex
- W2029228033
- Cited by
- 240
- References
- 25
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 5 · 2023: 10 · 2022: 11 · 2021: 11 · 2020: 13 · 2019: 12 · 2018: 20 · 2017: 29 · 2016: 24 · 2015: 23 · 2014: 27 · 2013: 28 · 2012: 12
- FWCI
- 19.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- exenatide, insulin glargine, type 2 diabetes, metformin, beta-cell function, insulin secretion, insulin sensitivity, disposition index, glycemic control, body weight, long-term treatment, GLP-1 receptor agonists
- MeSH terms
- Insulin Glargine, Exenatide, Adult, Aged, Blood Glucose, Body Weight, C-Peptide, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Peptides, Venoms, Insulin, Long-Acting, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.